OncoSec Medical Inc Beta
Quel est le Beta de OncoSec Medical Inc?
Le Beta de OncoSec Medical Inc est 0.00
Quelle est la définition de Beta?
BETA indique si une action est plus ou moins volatile que le marché dans son ensemble. Un bêta inférieur à 1 indique que l'action est moins volatile que le marché, tandis qu'un bêta supérieur à 1 indique que l'action est plus volatile. La volatilité est mesurée par la fluctuation du prix autour de la moyenne.
Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.
Beta des entreprises dans Health Care secteur sur NASDAQ par rapport à OncoSec Medical Inc
Que fait OncoSec Medical Inc?
oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar
Entreprises avec beta similaire à OncoSec Medical Inc
- Vision Marine Technologies a Beta de 0.00
- Ely Gold Royalties a Beta de 0.00
- Glacier Lake Resources a Beta de 0.00
- Magnum Mining and Exploration a Beta de 0.00
- Africa Opportunity Fund a Beta de 0.00
- Fulcrum Utility Services a Beta de 0.00
- OncoSec Medical Inc a Beta de 0.00
- Gullewa a Beta de 0.00
- S.A.L. Steel a Beta de 0.00
- Andina Acquisition III a Beta de 0.00
- Andina Acquisition III a Beta de 0.00
- Brilliant Acquisition a Beta de 0.00
- Indokem a Beta de 0.00